latanoprost; netarsudil dimesylate · Alcon Labs Inc · NDA 208259

Rocklatan

Earliest generic entry, as listed
14 Mar 2034

Blocked by patent: US 10588901, US 11020385, US 11185538, US 11197853, US 9415043, US 9931336, US 9993470.

Listed patents · 12 unexpired

PatentClaimsExpires
US 10588901drug substance, drug product, use U-1524 · sets the listed date14 Mar 2034
US 11020385use U-1524 · sets the listed date14 Mar 2034
US 11185538drug product · sets the listed date14 Mar 2034
US 11197853drug product · sets the listed date14 Mar 2034
US 9415043drug substance · sets the listed date14 Mar 2034
US 9931336drug substance, drug product, use U-1524 · sets the listed date14 Mar 2034
US 9993470drug substance, drug product, use U-1524 · sets the listed date14 Mar 2034
US 8394826drug substance, drug product, use U-152410 Nov 2030
US 10174017drug substance, drug product, use U-152427 Jan 2030
US 10654844drug substance, drug product, use U-152427 Jan 2030
US 11028081use U-152427 Jan 2030
US 11618748use U-152427 Jan 2030

Exclusivities · 0 unexpired

No unexpired exclusivities listed.

Paragraph IV certifications · 0

No Paragraph IV certification listed by FDA for this drug.

The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.

Event history

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.

Products covered · 1

NDA · productFormStrengthListed expiry
208259 · 001 · RLDsolution/drops, ophthalmic0.005%;EQ 0.02% BASE14 Mar 2034
Expired or delisted (5)
  • US 10532993 · use U-1524 · 11 Jul 2026
  • US 10882840 · use U-1524 · 11 Jul 2026
  • US 11021456 · use U-1524 · 11 Jul 2026
  • US 8450344 · substance, product, use U-1524 · 11 Jul 2026
  • US 9096569 · substance, product, use U-1524 · 11 Jul 2026